Drug Profile
Research programme: allergic asthma therapy - GlaxoSmithKline
Alternative Names: Birch pollen extract-protollin; Birch pollen extract/protollin; Protollin adjuvanted birch pollen extract; Protollin-birch pollen extract; Protollin/birch pollen extractLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ID Biomedical Corporation
- Developer GSK
- Class Allergy immunotherapies; Cysteine endopeptidases; Lipoproteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-asthma in Canada (Intranasal, Spray)
- 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
- 19 Apr 2005 Preclinical trials in Allergic asthma in Canada (Intranasal)